In the first study of its kind, researchers discovered that rifaximin, an antibiotic used to treat diarrhea, is an effective treatment for abdominal bloating and flatulence, including in irritable bowel syndrome (IBS) patients. This research is published in the February issue of The American Journal of Gastroenterology.
In this randomized double-blind placebo-controlled trial, researchers at the American University of Beirut in Lebanon treated 124 patients with rifaximin therapy and found that it was effective at relieving the symptoms of bloating and excess gaseousness by way of reducing the amount of hydrogen gas produced in the large intestine. And because rifaximin is non-absorbable, there are no side effects, making it suitable for chronic use.
Research has shown that these symptoms are common and often more disturbing to IBS patients, as well as being harder to treat, than the commonly associated diarrhea and constipation. Fortunately, among the patients with IBS in the trial, a favorable response was also noted, which lasted even through the post-treatment phase of the study.
Page: 1 Related medicine news :1
Contact: Sharon Agsalda
Blackwell Publishing Ltd.
. Reduced greenhouse gas emissions required to avoid dangerous increases in heat stress2
. Reduced dietary fat intake may decrease breast cancer recurrence3
. Reduced antibiotic prescribing is associated with increased hospital admissions4
. Reduced insulin in the brain triggers Alzheimers degeneration5
. Reduced brain volume may predict dementia in healthy elderly people6
. Depressed patients experience excessive inflammation during stressful situations7
. Parkinsons medication appears to trigger excessive gambling8
. Refusal of medical and surgical interventions common among chronically ill elderly9
. Needle-stick injuries are common but unreported by surgeons in training10
. Sleep-related breathing disorder common among aggressive, bullying schoolchildren11
. Nearly half of children in Kenya with common type of severe malaria affected neurologically